Mylan Comments on Copaxone Ruling; 2012 Earnings Guidance and 2013 Earnings Targets Remain Unchanged
Mylan Inc. (Nasdaq: MYL) today commented on an unfavorable ruling issued by the U.S. District Court for the Southern District of New York in relation to Teva's (NYSE: TEVA) patent infringement lawsuit against Mylan in relation to Mylan's proposed generic version of Copaxone®.
Mylan CEO Heather Bresch commented: "Although Mylan is disappointed in the Court's decision, and while we have not yet had the opportunity to review the Court's opinion, we fully intend to evaluate our options for an appeal once the Court's full opinion becomes available.
"Importantly and as previously stated, Mylan's earnings guidance for 2012 and earnings targets for 2013 are not reliant on the launch of a generic Copaxone, and therefore our expectations for these periods are unchanged."
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.